戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 c gadolinium-based contrast agent gadoterate meglumine.
2 sodium than after both saline and gadoterate meglumine.
3 be set off between ferric ion and gadoterate meglumine.
4 e but not by the macrocyclic GBCA gadoterate meglumine.
5 se in gadolinium in skin than did gadoterate meglumine.
6 administered<15 and >=15 doses of gadoterate meglumine.
7 gone more than 10 MR studies with gadoterate meglumine.
8 dministered <15 and >=15 doses of gadoterate meglumine.
9 n-recovery gradient-echo imaging, gadoterate meglumine (0.1 mmol/kg) was intravenously administered t
10 ved intraperitoneal injections of gadoterate meglumine (0.6 or 2.5 mmol per kilogram of body weight),
11 ) and contrast material-enhanced (gadoterate meglumine, 0.1 mmol/kg) T1-weighted images were separate
12 procedure, and almost all received ioxaglate meglumine; 161 (37%) patients had an increase in serum c
13 etate disodium arrived later than gadoterate meglumine (19.7 vs 16.3 seconds, respectively; P < .001)
14 ective intracoronary injections of sonicated meglumine (2 cm3).
15                 Ioversol 240 and iothalamate meglumine 43% were separately injected through three 9.6
16 , 40 seconds +/- 17; P < .001) or gadoterate meglumine (43 seconds +/- 21, P < .001) administration.
17 d after slow infusion of 20 mL of iodipamide meglumine 52% diluted in 80 mL of normal saline in 143 c
18  assessed in patients treated with tafamidis meglumine 80 mg in ATTR-ACT continuing in the LTE, compa
19  free acid 61 mg (bioequivalent to tafamidis meglumine 80 mg) following a protocol amendment.
20  with placebo, randomized (2:1) to tafamidis meglumine 80 or 20 mg.
21                                    Tafamidis meglumine, 80 mg or 20 mg (pooled cohort), vs placebo.
22        Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months.
23 ratios and the number of doses of gadoterate meglumine administered.
24 tate disodium, normal saline, and gadoterate meglumine, administered in random order in a single sess
25  one (2%; P = .62) had them after gadoterate meglumine administration, and none (P = .25) had them af
26 were much less apparent following gadoterate meglumine administration, where the presence of gadolini
27 after M2), dipyrone (after M3), and flunixin meglumine after surgical castration (M4).
28  after ingestion of 900 mL of 2% diatrizoate meglumine and diatrizoate sodium (Gastrografin; Bracco D
29 artic CT colonography (200 mL of diatrizoate meglumine and diatrizoate sodium).
30 xclusive use of macrocyclic GBCAs gadoterate meglumine and gadobutrol were analyzed.
31 d death under conditions wherein flunixin of meglumine and prednisolone were marginally effective.
32 ients, a dilute 2.5% solution of diatrizoate meglumine and sodium was administered orally or by means
33 nmol/g (gadobutrol), 0.04 nmol/g (gadoterate meglumine), and 0.07 nmol/g (gadoteridol).
34 tic resonance (MR) imaging group (gadoterate meglumine), and renal scintigraphy group ((99m)Tc).
35 trol, gadobenate dimeglumine, and gadoterate meglumine, and to determine potential risk factors for r
36 uch as sodium stibogluconate (Pentostam) and meglumine antimonate (Glucantime).
37 ailures was </=15% higher than achieved with meglumine antimoniate (1-sided test, alpha = .05).
38 ndomized to directly observed treatment with meglumine antimoniate (20 mg Sb/kg/d for 20 days; intram
39 onuclear cells (PBMCs) during treatment with meglumine antimoniate (MA) and clinical cure of human CL
40                                              Meglumine antimoniate (MA) remains the main treatment fo
41  treated with intralesional or intramuscular meglumine antimoniate but the mechanism has never been e
42                Miltefosine is noninferior to meglumine antimoniate for treatment of pediatric cutaneo
43 th local reactions at the injection sites of meglumine antimoniate in whom type IV hypersensitivity c
44 or L. chagasi declined during treatment with meglumine antimoniate or liposomal amphotericin B.
45  Cure rates <60% are observed in response to meglumine antimoniate therapy.
46 mpound 5 supported on gold nanoparticles and meglumine antimoniate was also effective in vivo and imp
47 ralesional infiltrations of Glucantime((R)) (meglumine antimoniate) for cutaneous leishmaniasis.
48 s over the course of systemic treatment with meglumine antimoniate, we revealed that a heightened and
49 efore and at the end of treatment (EoT) with meglumine antimoniate.
50 iltefosine and 31% (98% CI, 16.9%-45.2%) for meglumine antimoniate.
51 comparing gadoxetate disodium and gadoterate meglumine at free breathing.
52                                   Gadoterate meglumine did not differentially enhance the IRI kidney
53 te dimeglumine was equivalent to diatrizoate meglumine diluted to 40 mg iodine per milliliter.
54  potential liver donors underwent iodipamide meglumine-enhanced CT cholangiography.
55  recognized as a bright region on gadoterate meglumine-enhanced images.
56            A greater reduction in gadoterate meglumine-enhanced infarct area was measured in treated
57 ith either gadoxetate disodium or gadoterate meglumine enhancement.
58 de exposure in rats but not after gadoterate meglumine exposure.
59 metabolizing fenbendazole (FBZ) and flunixin meglumine (FLU) in swine liver.
60                 One such compound, tafamidis meglumine (Fx-1006A), has recently completed Phase II/II
61 ol/kg) and three reference GBCAs (gadoterate meglumine, gadobutrol, and gadobenate dimeglumine) at 0.
62 , a macrocyclic GBCA (gadobutrol, gadoterate meglumine, gadoteridol), or saline.
63 st agents (GBCAs) gadoteridol and gadoterate meglumine in a pediatric cohort.
64 njections of the macrocyclic GBCA gadoterate meglumine in pediatric patients, confirming previous stu
65  administration of 0.2 mmol/kg of gadoterate meglumine), including 3D MP2RAGE MRI.
66 CAs (gadobutrol, gadoteridol, and gadoterate meglumine), linear GBCAs (gadodiamide and gadobenate dim
67 e (linear contrast agent) but not gadoterate meglumine (macrocyclic contrast agent) led to pain hyper
68 59 participants were administered gadoterate meglumine (mean age, 59 years +/- 17; 85 women).
69 ormulated gadodiamide (n = 9) and gadoterate meglumine (n = 11), were administered intravenously (2.5
70 inium-based contrast agent (GBCA) gadoterate meglumine on the signal intensity (SI) of the dentate nu
71 ntly with the accumulated dose of gadoterate meglumine (P = 0.9064; rho = -0.0164 [95%]).
72 ntly with the accumulated dose of gadoterate meglumine (P=0.9064; rho=-0.0164 [95%]).
73 nations with the exclusive use of gadoterate meglumine (plus a final additional nonenhanced MR imagin
74  enhancement (CNR, 10.8), whereas gadoterate meglumine provided 5% (CNR, 6.9).
75            Skin of rats receiving gadoterate meglumine remained unchanged.
76 ed, and delayed enhancement (with gadoterate meglumine) sequences to measure global and regional LV f
77 r screening) or unexposed to only gadoterate meglumine underwent 3.0-T brain MRI with a dedicated hea
78   Receiving more than 10 doses of gadoterate meglumine was not associated with increased signal inten
79                                   Gadoterate meglumine was used as a non-oxidatively activated contro
80 ed contrast material (iohexol or iothalamate meglumine) was injected at either 2 mL/sec (25 patients
81                  P947, P1135, and gadoterate meglumine were injected into atherosclerotic apolipoprot
82 meglumine) or a macrocyclic GBCA (gadoterate meglumine) were analyzed retrospectively.